Grace Halsey

3 days ago | patientcareonline.com | Grace Halsey

A machine-learning algorithm developed by Phenomix Sciences and Mayo Clinic researchers can predict which patients are more likely to experience adverse events, especially nausea, from glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapies, according to findings presented at Digestive Disease Week (DDW) 2025.1,2 In a post-hoc analysis of a randomized controlled trial of liraglutide for weight loss, participants with a high Genetic Risk Score (GRS) for a measure termed “calories to...

6 days ago | patientcareonline.com | Grace Halsey

Temtokibart (LEO 138559), an investigational monoclonal antibody targeting the IL-22RA1 receptor subunit, achieved statistically significant improvements in eczema severity at the 3 highest tested doses in a phase 2b clinical trial of adults with moderate-to-severe atopic dermatitis (AD), according to topline results announced by LEO Pharma on May 9.1 The trial met its primary endpoint, demonstrating significant percentage reductions from baseline in Eczema Area and Severity Index (EASI)...

6 days ago | patientcareonline.com | Grace Halsey

The Moderna investigational multicomponent vaccine that combines protection against seasonal influenza and COVID-19 generated noninferior immune responses compared to separate standard vaccines, according to interim phase 3 data data from a trial involving more than 8,000 adults aged 50 years and older.1 Results from the study, published online May 7 in JAMA, showed that compared to standard-dose and high-dose influenza vaccines, mRNA-1083 not only met noninferiority criteria but also induced...

1 week ago | patientcareonline.com | Grace Halsey

A single mid-afternoon dose of inhaled beclomethasone may offer optimal control of asthma by better suppressing the nocturnal worsening of airway obstruction and inflammation, according to results from a small randomized crossover trial published in Thorax.

1 week ago | patientcareonline.com | Grace Halsey

The largest real-world study of its kind involving 273,770 individuals with atherosclerotic cardiovascular disease (ASCVD) found that every increase in levels of serum lipoprotein(a) [Lp(a)] is associated with increased risk of recurrent cardiovascular events.